# US 2025/0084153 A1 · Methods of treating al amyloidosis

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0084153 A1
- Document ID: US20250084153A1
- Status: Published application
- Kind: A1
- Application number: 18/273,854
- Filed: 2022-01-29
- Published: 2025-03-13
- Earliest claimed: 2021-01-29
- Assignees: Prothena Biosciences Limited
- Applicants: Prothena Biosciences Limited
- Inventors: Gene Kinney; Wagner Zago; Radhika Tripuraneni; Carol Karp
- Web page: https://patentgrep.com/patent/US20250084153A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

Antibody formulations and methods useful for treatment of patients with AL amyloidosis.

## Claims

### Claim 1

A method of treating a patient having AL amyloidosis, comprising:
(a) determining:
(i) the Mayo Stage of the patient's AL amyloidosis, or
(ii) the 6 minute walk test distance (6 MWD) and ejection fraction (EF) of the patient, or
(iii) the Mayo Stage and the EF of the patient; and
(b) selecting the patient for treatment with an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) if the patient:
(i) has Mayo Stage IV AL amyloidosis; or
(ii) has a 6 MWD≥30 meters and ≤550 meters; or
(iii) has a 6 MWD≥150 meters and an EF>50% at baseline; or
(iv) has Mayo Stage IV and a 6 MWD≥30 meters and ≤550 meters; or
(v) has Mayo Stage IV and EF>50% at baseline; or
(vi) has Mayo Stage IV, a 6 MWD≥150 meters and an EF>50% at baseline; and
(c) administering an effective dosage of the antibody, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 2 (depends on 1)

The method of claim 1, wherein the patient has Mayo Stage IV amyloidosis.

### Claim 3 (depends on 1)

The method of claim 1, wherein the patient has a 6 MWD≥150 meters and an EF>50%.

### Claim 4 (depends on 1)

The method of claim 1, wherein the patient has a 6 MWD≥30 meters and ≤550 meters.

### Claim 5 (depends on 2)

The method of claim 2, wherein the patient has an EF>50%.

### Claim 6 (depends on 5)

The method of claim 5, wherein the patient has a 6 MWD≥150 meters.

### Claim 7 (depends on 2)

The method of claim 2, wherein the patient has a 6 MWD≥30 meters and ≤550 meters.

### Claim 8

A method of treating a patient having AL amyloidosis, comprising administering an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105), wherein the patient has (a) Mayo Stage IV AL amyloidosis, (b) a 6 minute walk distance (6 MWD)≥30 meters and ≤550 meters, (c) a 6 MWD≥150 meters and EF>50%, (d) Mayo Stage IV and an EF>50%, (e) Mayo Stage IV and a 6 MWD≥30 meters and ≤550 meters, or (f) Mayo Stage IV and a 6 MWD≥150 meters and EF>50% and (g) the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 9 (depends on 8)

The method of claim 8, wherein the patient has Mayo Stage IV AL amyloidosis.

### Claim 10 (depends on 8)

The method of claim 8, wherein the patient has a 6 MWD≥150 meters and an EF>50%.

### Claim 11 (depends on 9)

The method of claim 9, wherein the patient has a 6 MWD≥150 meters and an EF>50%.

### Claim 12 (depends on 9)

The method of claim 9, wherein the patient has an EF>50%.

### Claim 13

A method of treating a patient having Mayo Stage IV AL amyloidosis and having NYHA class III or NYHA class IV, the method comprising administering to the patient a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 14 (depends on 13)

The method of claim 13, wherein the patient's NYHA class is reduced by at least two classes.

### Claim 15 (depends on 13, 14)

The method of any one of claim 13 or 14, wherein the patient's NYHA class is assessed nine or more months after treatment.

### Claim 16

A method of reducing the risk of mortality in a patient having Mayo Stage IV AL amyloidosis and having NYHA class III or NYHA class IV, the method comprising administering to the patient a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 17 (depends on 16)

The method of claim 16, wherein the risk of mortality is all-cause mortality.

### Claim 18 (depends on 16)

The method of claim 16, wherein the risk of mortality is cardiac mortality.

### Claim 19 (depends on 16, 17, 18)

The method of any one of claims 16 to 18, wherein the risk of mortality is assessed nine or more months after treatment.

### Claim 20 (depends on 16, 17, 18, 19)

The method of any one of claims 16-19, wherein the risk of mortality is reduced by at least 15% as compared to the risk of mortality in a control population.

### Claim 21

A method of reducing the risk of hospitalization in a patient having Mayo Stage IV AL amyloidosis, the method comprising administering to the patient a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 22 (depends on 21)

The method of claim 21, wherein the risk of hospitalization in the patient is reduced by at least 20% as compared to the risk of hospitalization in a control population.

### Claim 23

A method of increasing the number of days alive out of hospital (DAOH) in a patient Mayo Stage IV amyloidosis, the method comprising administering to the patient a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 24 (depends on 23)

The method of claim 23, wherein the number of DAOH increases by at least 20 days after one month of treatment as compared to a control population.

### Claim 25 (depends on 23, 24)

The method of claim 23 or 24, wherein the number of DAOH increases by at least 100 days after six months of treatment as compared to DAOH in a control population.

### Claim 26 (depends on 23, 24, 25)

The method of any one of claims 23-25, wherein the number of DAOH increases by at least 300 after twelve months of treatment as compared to DAOH in a control population.

### Claim 27 (depends on 23, 24, 25, 26)

The method of any one of claims 23-26, wherein the number of DAOH increases by at least 600 after 24 months of treatment as compared to DAOH in a control population.

### Claim 28 (depends on 23, 24, 25, 26, 27)

The method of any one of claims 23-27, wherein the number of DAOH increases by at least 900 after 48 months of treatment as compared to DAOH in a control population.

### Claim 29

A method of reducing NTproBNP in a patient having Mayo Stage IV AL amyloidosis, the method comprising administering to the patient a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 30 (depends on 29)

The method of claim 29, wherein NTproBNP is reduced by at least 31% from a baseline after 3 months of treatment.

### Claim 31 (depends on 29, 30)

The method of claim 29 or 30, wherein NTproBNP is reduced by at least 45% from a baseline after 3 months of treatment.

### Claim 32 (depends on 25, 26, 27, 28, 29, 30, 31)

The method of any one of claims 25-31, wherein NTproBNP is reduced by at least 60% from a baseline after 3 months of treatment.

### Claim 33 (depends on 29, 30, 31, 32)

The method of any one of claims 29-32, wherein NTproBNP is reduced by at least 60% from a baseline to a nadir >400 pg/ml after 3 months of treatment.

### Claim 34 (depends on 29, 30, 31, 32, 33)

The method of any one of claims 29-33, wherein NTproBNP is reduced to a nadir <400 pg/ml after 3 months of treatment.

### Claim 35 (depends on 29, 30, 31, 32, 33, 34)

The method of any one of claims 29-34, wherein NTproBNP is reduced by at least 45% from a baseline after 6 months of treatment.

### Claim 36 (depends on 29, 30, 31, 32, 33, 34, 35)

The method of any one of claims 29-35, wherein NTproBNP is reduced by at least 60% from a baseline after 6 months of treatment.

### Claim 37 (depends on 29, 30, 31, 32, 33, 34, 35, 36)

The method of any one of claims 29-36, wherein NTproBNP is reduced by at least 60% from a baseline to a nadir >400 pg/ml after 6 months of treatment.

### Claim 38 (depends on 29, 30, 31, 32, 33, 34, 35, 36, 37)

The method of any one of claims 29-37, wherein NTproBNP is reduced to a nadir <400 pg/ml after 3 months of treatment.

### Claim 39

A method of improving cardiac response rate in a patient having Mayo Stage IV AL amyloidosis, the method comprising administering a therapeutically effective amount of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 40 (depends on 39)

The method of claim 39, wherein the cardiac response rate increases at least 30% after 6 months of treatment as compared to baseline.

### Claim 41 (depends on 39, 40)

The method of any claims 39 to 40, wherein the cardiac response rate increases at least 50% after 12 months of treatment as compared to baseline.

### Claim 42 (depends on 39, 40, 41)

The method of any one of claims 39-41, wherein the cardiac response rate increases at least 75% after 12 months of treatment as compared to baseline.

### Claim 43

A method of improving a six minute walk test (6 MWT) in a patient having Mayo Stage IV AL amyloidosis, the method comprising administering a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 44 (depends on 43)

The method of claim 43, wherein the 6 MWT achieved is at least 300 meters.

### Claim 45 (depends on 43, 44)

The method of claim 43 or 44, wherein the 6 MWT achieved is at least 300 meters after treatment for 12 months.

### Claim 46 (depends on 43, 44, 45)

The method of any one of claims 43-45, wherein the 6 MWT improves at least 33 meters as compared to baseline.

### Claim 47 (depends on 43, 44, 45, 46)

The method of any one of claims 43-46, wherein the 6 MWT improves at least 33 meters after 12 months of treatment as compared to baseline.

### Claim 48 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43-47, wherein the 6 MWT achieved is at least 300 meters after treatment for 18 months.

### Claim 49 (depends on 43, 44, 45, 46, 47)

The method of any one of claims 43-47, wherein the 6 MWT improves at least 33 meters after 18 months of treatment as compared to baseline.

### Claim 50

A method of increasing a Kansas City Cardiomyopatthy Questionnaire (KCCQ) score in a patient having Mayo Stage IV AL amyloidosis, the method comprising administering a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 51 (depends on 50)

The method of claim 50, wherein the KCCQ score increased by at least 5 after 3 months of treatment as compared to baseline.

### Claim 52 (depends on 50, 51)

The method of claim 50 or 51, wherein the KCCQ score increased by at least 10 after 3 months of treatment as compared to baseline.

### Claim 53 (depends on 50, 51, 52)

The method of any one of claims 50-52, wherein the KCCQ score increased by at least 15 after 3 months of treatment as compared to baseline.

### Claim 54 (depends on 50, 51, 52, 53)

The method of any one of claims 50-53, wherein the KCCQ score improves by at least 20 after 3 months of treatment as compared to baseline.

### Claim 55 (depends on 50, 51, 52, 53, 54)

The method of any one of claims 50-54, wherein the KCCQ score improves by at least 5 after 12 months of treatment as compared to baseline.

### Claim 56 (depends on 50, 51, 52, 53, 54, 55)

The method of any one of claims 50-55, wherein the KCCQ score improves by at least 10 after 12 months of treatment as compared to baseline.

### Claim 57 (depends on 50, 51, 52, 53, 54, 55, 56)

The method of any one of claims 50-56, wherein the KCCQ score improves by at least 15 after 12 months of treatment as compared to baseline.

### Claim 58 (depends on 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 50-57, wherein the KCCQ score improves by at least 20 after 12 months of treatment as compared to baseline.

### Claim 59

A method of increasing Major Organ Deterioration Progression Free Survival in a patient having Mayo Class IV AL amyloidosis, the method comprising administering to the patient a therapeutically effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) amount, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 60 (depends on 59)

The method of claim 59, wherein NTproBNP is reduced by at least 31% from a baseline after 3 months of treatment.

### Claim 61 (depends on 59, 60)

The method of claim 59 or 60, wherein NTproBNP is reduced by at least 45% from a baseline after 3 months of treatment.

### Claim 62 (depends on 59, 60, 61)

The method of any one of claims 59-61, wherein NTproBNP is reduced by at least 60% from a baseline after 3 months of treatment.

### Claim 63 (depends on 59, 60, 61, 62)

The method of any one of claims 59-62, wherein NTproBNP is reduced by at least 60% from a baseline to a nadir >400 pg/ml after 3 months of treatment.

### Claim 64 (depends on 59, 60, 61, 62, 63)

The method of any one of claims 59-63, wherein NTproBNP is reduced to a nadir <400 pg/ml after 3 months of treatment.

### Claim 65 (depends on 59, 60, 61, 62, 63)

The method of any one of claims 59-63, wherein NTproBNP is reduced by at least 45% from a baseline after 6 months of treatment.

### Claim 66 (depends on 59, 60, 61, 62, 63, 64, 65)

The method of any one of claims 59-65, wherein NTproBNP is reduced by at least 60% from a baseline after 6 months of treatment.

### Claim 67 (depends on 59, 60, 61, 62, 63, 64, 65, 66)

The method of any one of claims 59-66, wherein NTproBNP is reduced by at least 60% from a baseline to a nadir >400 pg/ml after 6 months of treatment.

### Claim 68 (depends on 59, 60, 61, 62, 63, 64, 65, 66, 67)

The method of any one of claims 59-67, wherein NTproBNP is reduced to a nadir <400 pg/ml after 3 months of treatment.

### Claim 69

The method of any of the preceding claims, wherein the antibody comprises a light chain variable region comprising three complementarity determining regions of 2A4, 7D8 or 11-1F4, and a heavy chain variable region comprising three complementarity determining regions of 2A4, 7D8 or 11-1F4, respectively.

### Claim 70

The method of any of the preceding claims, wherein the antibody is a humanized version of 2A4.

### Claim 71 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70)

The method of any of claims 1-70, wherein the antibody is a humanized or chimeric version of 11-1F4.

### Claim 72 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71)

The method of any of claims 1-71, wherein the antibody comprises a light chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: 3, 4 and 5, or SEQ ID NOs: 16, 17, and 18, and a heavy chain variable region comprising three complementarity determining regions set forth as SEQ ID NOs: 6, 7 and 8, or SEQ ID NOs: 19, 20, and 21.

### Claim 73 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any of claims 1-72, wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1 or 14.

### Claim 74 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any of claims 1-72, wherein the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2 or 15.

### Claim 75 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74)

The method of any of claims 1-74, wherein the light chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 1 or 14, and the heavy chain variable region comprises the amino acid sequence set forth as SEQ ID NO: 2 or 15.

### Claim 76 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75)

The method of any of claims 1-75, wherein the antibody comprises a light chain comprising the amino acid sequence set forth as SEQ ID NO: 10, and a heavy chain comprising the amino acid sequence set forth as SEQ ID NO: 11, 12 or 13.

### Claim 77 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76)

The method of any of claims 1-76, wherein the antibody comprises a light chain comprising the amino acid sequence set forth as SEQ ID NO: 10, and a heavy chain comprising the amino acid sequence set forth as SEQ ID NO: 12.

### Claim 78 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72, 73, 74, 75, 76, 77)

The method of any of claims 1-77, wherein the antibody is birtamimab.

### Claim 79

The method of any of the preceding claims, wherein the patient is newly diagnosed and AL amyloidosis treatment naïve.

### Claim 80 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43, 44, 45, 46, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62, 63, 64, 65, 66, 67, 68, 69, 70, 71, 72)

The method of any of claims 1-72, wherein the patient previously received or concomitantly receives treatment with melphalan, prednisone, dexamethasone, bortezomib, cyclophosphamide, lenalidomide, doxorubicin, doxycycline, autologous transplant, or a combination thereof.

### Claim 81 (depends on 2, 5, 9)

The method of any of claims 2, 5, 9, or 11, comprising administering to the Mayo Stage IV patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105) and the patient has not previously received or concomitantly receives daratumumab, thereby reducing the patient's risk of mortality by at least about 35%.

### Claim 82

A method of treating a patient with AL amyloidosis, comprising:
a) determining that the patient has a 6 minute walk distance (6 MWD)≥30 meters and ≤550 meters or a 6 MWD≥150 meters and an ejection fraction (EF)>50%;
b) selecting the patient for treatment with an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105); and
c) administering an effective dosage of the antibody, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 83

A method of treating a patient with AL amyloidosis who has a demonstrated 6 minute walk distance (6 MWD) of ≥30 meters and ≤550 meters or a 6 MWD greater than or equal to 150 meters and an ejection fraction (EF) of more than 50%, comprising administering to the patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105), wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 84

A method of reducing the risk of mortality in a patient with AL amyloidosis by at least 45%, comprising administering to the patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105), wherein the patient has Mayo Stage IV AL amyloidosis and/or has a demonstrated 6 minute walk distance (6 MWD)≥30 meters and ≤550 meters, or a 6 MWD of greater than or equal to 150 meters and an ejection fraction (EF) of more than 50%, or the patient has Mayo Stage IV AL amyloidosis and an EF of >50%, wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 85 (depends on 84)

The method of claim 84, wherein the risk of mortality is of all-cause mortality.

### Claim 86 (depends on 85)

The method of claim 85, wherein the risk of all-cause mortality is reduced by at least about 48.9%.

### Claim 87 (depends on 85)

The method of claim 85, wherein the risk of all-cause mortality is reduced by at least about 50%.

### Claim 88 (depends on 85)

The method of claim 85, wherein the risk of all-cause mortality is reduced by at least about 50.2%.

### Claim 89 (depends on 85)

The method of claim 85, wherein the risk of all-cause mortality is reduced by at least about 60%.

### Claim 90 (depends on 85)

The method of claim 85, wherein the risk of all-cause mortality is reduced by at least about 70%.

### Claim 91 (depends on 85)

The method of claim 85, wherein the risk of all-cause mortality is reduced by at least about 79.9%.

### Claim 92 (depends on 85)

The method of claim 85, wherein the risk of all-cause mortality is reduced by at least about 81.5%.

### Claim 93 (depends on 84)

The method of claim 84, wherein the risk of mortality is of cardiac mortality.

### Claim 94 (depends on 93)

The method of claim 93, wherein the risk of cardiac mortality is reduced by at least about 75%.

### Claim 95

The method of 94, wherein the risk of cardiac mortality is reduced by at least about 62.2%.

### Claim 96 (depends on 81, 82, 83, 84, 85, 86, 87, 88, 89, 90, 91, 92, 93, 94, 95)

The method of any of claims 81-95, wherein the antibody is birtamimab.

### Claim 97

The method of any of the preceding claims, wherein the patient exhibits improvement in the 36-Item Short Form Survey Physical Component Score (SF-36 PCS) or SF-36v2 following treatment with the antibody.

### Claim 98 (depends on 90)

The method of claim 90, wherein after nine months of treatment the change in the patient's score on the SF-36 PCS or SF-36v2 is at least 5 points higher relative to a different patient at the same time point who has not been administered the antibody.

### Claim 99

The method of any of the preceding claims, wherein the effective dosage of the antibody is administered from a pharmaceutical formulation comprising the antibody at a concentration within the range from about 1 mg/mL to about 100 mg/mL.

### Claim 100

The method of any of the preceding claims, wherein the dosage is from about 0.5 mg/kg to about 30 mg/kg and the antibody is administered intravenously or subcutaneously at a frequency of from about weekly to about quarterly.

### Claim 101 (depends on 100)

The method of claim 100, wherein the antibody is present at a concentration of about 50 mg/mL.

### Claim 102 (depends on 99, 100, 101)

The method of any of claims 99-101, wherein the dosage is administered intravenously following the transfer of an amount of the formulation required for the dosage from a vial to an intravenous bag containing a liquid.

### Claim 103 (depends on 99, 100, 101, 102)

The method of any claims 99-102, wherein the dosage is about 24 mg/kg and the antibody is administered intravenously every 28 days.

### Claim 104

The method of any of the preceding claims, wherein the duration of the treatment is at least 9 months.

### Claim 105 (depends on 104)

The method of claim 104, wherein the duration of the treatment is at least 12 months.

### Claim 106

The method of any of the preceding claims, wherein the duration is effective to achieve or maintain at least about a 3 point increase from baseline in SF-36 PCS or SF-36v2.

### Claim 107

The method of any of the preceding claims, wherein the antibody is a Fab, Fab′, F(ab′)2, F(ab)c, Dab, nanobody, or Fv.

### Claim 108

The method of any of the preceding claims, wherein treatment results in a 20% relative reduction in hospitalization.

### Claim 109

The method of any of the preceding claims, wherein treatment results in a 310% to 60% reduction in NTproBNP from a baseline.

### Claim 110

The method of any of the preceding claims, wherein treatment results in a >60% reduction in NTproBNP from a baseline to a nadir NTproBNP>400 pg/mL.

### Claim 111

The method of any of the preceding claims, wherein treatment results in a nadir NTproBNP<400 pg/mL.

### Claim 112

The method of any of the preceding claims, wherein treatment results in at least a 5 point change to a 20 point change in the Kansas City Cardiomyopathy Questionnaire (KCCQ) score.

### Claim 113

The method of any of the preceding claims, wherein after treatment of 12 months results in at least a 33 meter improvement in the 6 MWT.

### Claim 114

A method of improving a 6 minute walk distance (6 MWD) in a patient having AL amyloidosis, comprising administering to the patient an effective dosage of an antibody which competes for binding to human amyloid A peptide or human kappa or lambda light chain immunoglobulin with 2A4 (ATCC Accession Number PTA-9662) or 7D8 (ATCC Accession Number PTA-9468), or competes for binding to kappa light chain immunoglobulin with 11-1F4 (ATCC Accession Number PTA-105), wherein the patient has not previously received or does not concomitantly receive daratumumab.

### Claim 115 (depends on 114)

The method of claim 114, wherein the AL amyloidosis is Mayo Stage IV AL amyloidosis.

### Claim 116 (depends on 114, 115)

The method of claim 114 or 115, wherein an ejection fraction (EF) of the patient is >50%.

### Claim 117 (depends on 114, 115, 116)

The method of any of claims 114 to 116, wherein the antibody in birtamimab.
